Inpatient and Outpatient Orderable

Vedolizumab and Vedolizumab Antibody Build info

Synonyms

  • VEDOLIZUMAB & ANTI-VEDOLIZUMAB AB
  • VEDOLIZUMAN AND ANTI-VEDOLIZUMAB AB
  • VEDILZ
  • LAB12490

Procedure Name

VEDOLIZUMAB & ANTI-VEDOLIZUMAB AB

Procedure Master Number

LAB12490

Cerner Name

Vedolizumab and Anti-Vedolizumab Ab

Procedure ID

137053

Clinical Info

Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making.

Specimen Sources

 Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

 Blood

Container

Gold Top Tube

Collection Instructions

Container/Tube: Gold Top Tube or Red Top Tube
Specimen: 2 mL serum ( 1 mL min)
Transport Temperature: Refrigerated

Specimen Volume

2 mL serum (1 mL min)

Transport Instructions

Specimen Stability

14 Days Room Temperature
14 Days Refrigerated
14 Days Frozen

Methodology

Electrochemiluminescence Immunoassay (ECLIA)

Days Performed

TAT: 9-16 Days

Performing Laboratory

LabCorp

CPT

80280,82397

PDM

 1759547

Only Orderable at Locations:

 Orderable Everywhere

Results
Component Name Base Name Common Name External Name
VEDOLIZUMAB VEDOLIZUMAB VEDOLIZUMAB Vedolizumab
ANTI-VEDOLIZUMAB ANTIVEDOLIZ ANTI VEDOLIZUMAB Anti-Vedolizumab Antibody

Result Interpretation

See Report

   In the absence of anti-vedolizumab antibodies, the vedolizumab drug level reflects the total vedolizumab concentration. In the presence of anti-vedolizumab antibodies, the vedolizumab concentration reflects the antibody-unbound fraction of vedolizumab.
The presence of vedolizumab drug, even at concentrations well above target treatment levels , does not interfere with anti-vedolizumab antibody measurement. All positive anti-vedolizumab antibody results are verified by a confirmatory test.
Limitations
Drug half-life should be taken into consideration when interpreting concentrations measured in non-trough collections.

Forms
edit